网络药理学探究神效瓜蒌散治疗乳腺癌作用机制

Action mechanism of Shenxiaogualousan in treatment of breast cancer by network pharmacology method

目的:通过网络药理学探究神效瓜蒌散治疗乳腺癌的机制。方法:设置不同剂量神效瓜蒌散组,对乳腺癌细胞SKBR-3进行台盼蓝染色法、MTS试验、划痕实验等体外实验验证其治疗乳腺癌的作用,通过网络药理学构建有效成分-作用靶点网络,预测神效瓜蒌散作用于乳腺癌的机制,最后通过Westernblot实验验证预测。结果:神效瓜蒌散能够在体外抑制乳腺癌细胞SKBR-3的增殖和迁移,通过网络药理学预测神效瓜蒌散可能通过ER、HSP90等靶点作用于乳腺癌发挥其抗肿瘤作用,通过Westernblot观察到神效瓜蒌散作用的乳腺癌细胞SKBR-3的ERα表达下降。结论:神效瓜蒌散可能主要通过抑制ER内分泌通路治疗乳腺癌。

Objective: To explore the Shenxiaogualousan mechanism for the treatment of breast cancer by the network pharmacology and in vitro experiments. Methods: Shenxiaogualousan groups given different dosages were established in the present study. Trypan blue staining, MTS test, scratch test and other in vitro tests were used to verify the effect of Shenxiaogualousan on breast cancer cell line SKBR-3. Furthermore, the mechanism of Shenxiaogualousan in breast cancer was predicted by constructing an active component-action target network through network pharmacology, followed by verification using western blot. Results: The effective Shenxiaogualousan could inhibit the proliferation and migration of breast cancer cell line SKBR-3 in vitro. Network pharmacology predicted that the effective Shenxiaogualousan could have anti-tumor effect on breast cancer through ER, HSP90 and other targets. Furthermore, western blot results showed that the expression of ERα was decreased in SKBR-3 cells after treated with the effective Shenxiaogualousan. Conclusion: The effective Shenxiaogualousan may have a role in the treatment of breast cancer through the inhibition of ER endocrine pathways.